Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Blau

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Blut|November 1, 1989
Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3'-deoxy-3'-fluorothymidine in comparison to 3'-azido-3'-deoxythymidineI W Blau, E Elstner, M Waechter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trialO Penack, S Schwartz, P Martus, et al.
Bone Marrow Transplantation|March 21, 2000
Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating studyN Basara, B Schmetzer, I W Blau, et al.
Bone Marrow Transplantation|January 20, 2009
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCTM Schmidt-Hieber, S Schwarck, A Stroux, et al.
Bone Marrow Transplantation|October 3, 1998
Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysisM E Bischoff, W Blau, T Wagner, et al.
Investigational New Drugs|November 17, 2010
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell linesMartin Schmidt-Hieber, Robert Dabrowski, Andreas Weimann, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 22, 2016
Anti-Aspergillus immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipientsJ-H Erdmann, B Graf, I W Blau, et al.
Journal of Pain and Symptom Management|November 1, 1996
Changing the relationship among nurses' knowledge, self-reported behavior, and documented behavior in pain management: does education make a difference?J A Dalton, W Blau, J Carlson, et al.
Annals of Hematology|October 24, 2000
Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantationJ Chemnitz, M Fuchs, W Blau, et al.
International Journal of Hematology|May 22, 2010
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletionMartin Schmidt-Hieber, S Schwarck, A Stroux, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Blut|November 1, 1989
Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3'-deoxy-3'-fluorothymidine in comparison to 3'-azido-3'-deoxythymidineI W Blau, E Elstner, M Waechter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trialO Penack, S Schwartz, P Martus, et al.
Bone Marrow Transplantation|March 21, 2000
Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating studyN Basara, B Schmetzer, I W Blau, et al.
Bone Marrow Transplantation|January 20, 2009
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCTM Schmidt-Hieber, S Schwarck, A Stroux, et al.
Bone Marrow Transplantation|October 3, 1998
Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysisM E Bischoff, W Blau, T Wagner, et al.
Investigational New Drugs|November 17, 2010
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell linesMartin Schmidt-Hieber, Robert Dabrowski, Andreas Weimann, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 22, 2016
Anti-Aspergillus immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipientsJ-H Erdmann, B Graf, I W Blau, et al.
Journal of Pain and Symptom Management|November 1, 1996
Changing the relationship among nurses' knowledge, self-reported behavior, and documented behavior in pain management: does education make a difference?J A Dalton, W Blau, J Carlson, et al.
Annals of Hematology|October 24, 2000
Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantationJ Chemnitz, M Fuchs, W Blau, et al.
International Journal of Hematology|May 22, 2010
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletionMartin Schmidt-Hieber, S Schwarck, A Stroux, et al.
Pageof 13